Duration: (28:28) ?Subscribe5835 2025-02-22T08:35:09+00:00
CIPO2015: T Cells as Biotherapeutics for Solid Tumors
(28:28)
CIPO2015: Adoptive T Cell Immunotherapy Targeting the Minor Histocompatibility Antigen HA-1
(15:2)
CIPO2015: Pre-clinical and Clinical Development of CD22-Targeted CAR T Cells
(16:28)
CIPO2015: Enhancers Delineate Disease-Associated Regulatory Nodes in T Cells
(25:27)
CIPO2015: Optimizing Adoptive Immunotherapy for Cancer
(27:33)
CIPO2015: Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box
(20:21)
CIPO2015: Targeting GD2 w/ 3F8 \u0026 B7-H3 w/ 8H9: Lessons Learned \u0026 Next Generation Therapeutics
(33:10)
CIPO2015: Effective Ablation of Chimeric Antigen Receptor-Modified T Cells for AML with Alemtuzumab
(15:49)
CIPO2015: CD19 CAR T Cells During Therapy in Relapsed ALL Pediatric and Young Adult Patients
(16:18)
Quantum Biology: The Hidden Nature of Nature
(1:35:37)
Engineering Better CAR T Cells: An Interview with CRI STAR Yvonne Chen, PhD
(16:43)
Cell surface markers: CD3, CD4, CD8, CD19, CD28, CD16, CD56
(21:24)
Deciphering CAR-T Cells: Exploring Functional Mechanisms to Drive Next Generation Immunotherapy
(1:1:36)
Immune System - Natural Killer Cell
(3:2)
Cytotoxic T (Tc) cells or Killer T cells (FL-Immuno/33)
(6:32)
Immunology - Lymphocytes (B cells, T cells, NK cells, and NKT cells)
(4:50)
Bispecific Antibodies for T‐Cell Redirection Therapy
(21:32)
NKT Cell Development and Activation: Implications in Cancer Immunotherapy
(1:3:53)
Brandl's Basics: The NK cell
(10:48)
CIPO2015: Durable Immune Control of ALL Requires a Multi-Antigen Immune Response
CIPO2015: Genetically Engineered Macrophages: Overcoming the Brain Tumor Microenvironment
(18:38)
CIPO2015: Clues from Graft-Versus-Host Disease to Design Successful Immunotherapy
(31:4)
CIPO2015: Dual Targeting of CD19 \u0026 CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Receptor
(11:22)
CIPO2015: Exploiting Natural \u0026 Engineered Properties of NKT Cells for Immunotherapy of Neuroblastoma
(32:38)
CIPO2015: NKT Cells Selectively Target M2-like Macrophages in Neuroblastoma Tumor Microenvironment
(14:32)
CIPO2015: Allogeneic Transplantation as a Platform for Post-Transplant Immunotherapy
(32:13)
CIPO2015: Dissecting Tumor Heterogeneity with Single-Cell Transcriptomics
(31:44)
CIPO2015: Enhancing Graft Vs. Tumor Effect Against Neuroblastoma Using an Anti-GD2 Immunocytokine
(13:38)
CIPO2015: Cancer-Targeted IL-12 Controls Human RMS by Senescence Induction and Differentiation
(16:37)
CIPO2015: Anti-GD2 mAb and Next Generation mAb-Based Agents, KIR, Cytokines and Combination Therapy
(32:50)